Medicine, Cardiology Division

Grants

Grants per year 1999 2014 2015 2016 2017 2018 2019 2020 2021 2031

• 5 Not started
• 230 Active
• 554 Finished

Grants per year

Search results

• Active

  Development of anti-LTBP4 as a biologic to treat Neuromuscular Diseases

  Demonbreun, A. R. & McNally, E. M.

  National Institute of Neurological Disorders and Stroke

  6/16/22 → 5/31/24

  Project: Research project

  • Carrier Proteins 100%
  • Neuromuscular Diseases 80%
  • Duchenne Muscular Dystrophy 48%
  • Lead 28%
  • Muscles 24%

• Prot# CY 6031 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of CK3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

  Choudhury, L.

  Cytokinetics, Inc.

  5/24/22 → 5/24/25

  Project: Research project

• 2-Generation Interventions to Improve Cardiovascular Health in Indiana and Illinois Through Home Visiting (2-NOURISH)

  Khan, S. S., Tandon, D., Brown, C. H., O'Brien, M. J., Van Horn, L., Welty, L. J. & Yee, L. M.

  National Heart, Lung, and Blood Institute

  5/16/22 → 4/30/24

  Project: Research project

• Prot#RIV-HU6-2201: NUECL for Exploratory Phase 2A, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of HU6 in Subjects with Obese Heart Failure with Preserved Ejection Fra

  Shah, S. J.

  Rivus Pharmaceuticals, Inc.

  4/26/22 → 4/26/25

  Project: Research project

• Prot#EX9536-4773: Effect of Semaglutide 2.4 mg once-weekly on function and symptoms in subjects with obesity-related heart failure with preserved ejection fraction, and type 2 diabetes

  Patel, R. B.

  Novo Nordisk Inc.

  4/11/22 → 4/11/25

  Project: Research project

• New roles of endothelial regrowth in ischemic tissue recovery and regeneration

  Kume, T.

  National Heart, Lung, and Blood Institute

  4/1/22 → 3/31/26

  Project: Research project

  • Regeneration 100%
  • Blood Vessels 78%
  • Lymphatic Vessels 63%
  • Endothelial Cells 49%
  • Catenins 33%

• Rapid Cardiovascular MRI for Screening Microvascular Angina in COVID-19 Survivors

  Kim, D., Lee, D. C., Allen, B. D., Ison, M. G., Kalhan, R. & Markl, M.

  American Heart Association

  4/1/22 → 3/31/25

  Project: Research project

  • SARS Virus 100%
  • Microvascular Angina 81%
  • Magnetic Resonance Spectroscopy 76%
  • Survivors 44%
  • Clostridium perfringens epsilon-toxin 39%

• Measurement of ab-initio physiomarker using wearable sensors to predict aneurysm growth and formation

  Pandit, J. A., Patankar, N. A. & Rogers, J. A.

  National Institutes of Health

  3/21/22 → 3/20/23

  Project: Research project

• PEAKS Registry: Prospective Evaluation Analysis and Kinetics of IV Sotalol

  Verma, N.

  University of Utah, AltaThera Pharmaceuticals, LLC

  3/16/22 → 3/16/25

  Project: Research project

• Momentum 3 IDE - 5 Year Outcomes: A Retrospective Study to Determine Up to 5 Year Clinical Outcomes in Subjects Previously Randomized in the MOMENTUM 3 Study

  Rich, J. D.

  Abbott Laboratories

  3/8/22 → 3/7/23

  Project: Research project

• A Prospective, Multi-Center, Randomized, Controlled, Single Blind Clinical Trial Evaluating the Safety and Efficacy of the Cordella™ Pulmonary Artery Sensor System in New York Heart Association (NYHA) Class III Heart Failure Patients

  Raza, Y.

  Endotronix, Inc.

  3/1/22 → 3/1/25

  Project: Research project

• Northwestern University Echo Core Lab (NUECL) for ALLEVIATE-HF-3 STUDY: The Safety and Efficacy of a Percutaneously Created Interatrial Shunt with the Alleviant System in Patients with Chronic Heart Failure and Preserved or Mid-Range Left Ventricular Ejec

  Narang, A.

  Alleviant Medical, Inc.

  2/24/22 → 2/23/31

  Project: Research project

• Mac-Lab/CardioLab V8.0 System Performance Evaluation

  Kim Koss, S. S. & Knight, B. P.

  GE Precision Healthcare LLC

  2/18/22 → 2/17/23

  Project: Research project

• CARDIALEN CL007: Novel Therapy System for Atrial Fibrillation

  Knight, B. P.

  Cardialen, Inc., National Heart, Lung, and Blood Institute

  2/1/22 → 8/31/22

  Project: Research project

  • Atrial Fibrillation 100%
  • Electric Stimulation Therapy 66%
  • Safety 27%
  • Therapeutics 12%

• New and Disruptive Therapeutic Approaches to Target Fundamental Molecular Mechanisms Underlying Atrial Fibrillation

  Arora, R. K., Wasserstrom, J. A. & Yoo, S.

  National Heart, Lung, and Blood Institute

  1/20/22 → 12/31/28

  Project: Research project

  • Atrial Fibrillation 100%
  • Genetic Therapy 21%
  • Therapeutics 11%
  • Animal Models 8%
  • Atrial Remodeling 8%

• LUX-Dx Heart Failure Sensors in an Insertable Cardiac Monitor System Clinical Study

  Okwuosa, I. S.

  Boston Scientific Corporation

  1/19/22 → 1/19/24

  Project: Research project

• PRE-DETERMINE: Biologic Markers and MRI SCD Cohort Study

  Lee, D. C.

  Leipzig Heart Institute GmbH, European Commission

  1/17/22 → 6/30/22

  Project: Research project

  • Digital Imaging and Communications in Medicine (DICOM) 100%
  • Magnetic resonance 87%
  • Imaging techniques 64%
  • Data transfer 49%
  • Information technology 21%

• Evolutionary advantage of heterozygous PAI-1 deficiency in humans

  Vaughan, D. E.

  Norn Group

  1/1/22 → 12/31/24

  Project: Research project

  • Plasminogen Activator Inhibitor-1 Deficiency 100%
  • Plasminogen Activator Inhibitor 1 80%
  • Morbidity 21%
  • Loss of Function Mutation 20%
  • Emphysema 20%

• Prot#D6402C00001: A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Efficacy, Safety and Tolerability of Oral AZD9977 and Dapagliflozin Treatment in Patients with Heart Failure with Left Ventricular Ejection Frac

  Wilcox, J. E.

  Parexel, AstraZeneca Pharmaceuticals LP

  12/21/21 → 12/21/24

  Project: Research project

• Prot#D6580C00010: A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for up to 48 Weeks in Participants with Heart Failure With Left Ventricular Ej

  Patel, R. B.

  AstraZeneca Pharmaceuticals LP

  12/16/21 → 12/16/24

  Project: Research project

• Role of mRNA-binding protein tristetraprolin in cardiac mRNA regulation and the development of heart failure

  Ardehali, H.

  National Heart, Lung, and Blood Institute

  12/15/21 → 11/30/25

  Project: Research project

  • Tristetraprolin 100%
  • Carrier Proteins 27%
  • Heart Failure 26%
  • Branched Chain Amino Acids 25%
  • Messenger RNA 25%

• Define AFIB

  Patil, K. D.

  Medtronic, Inc.

  12/8/21 → 12/8/24

  Project: Research project

• PRegnancy OuTcomEs and subclinical Cardiovascular disease sTudy: (PROTECT)

  Khan, S. S., Allen, N. B., Greenland, P., Grobman, W. A., Petito, L. C., Shah, S. J. & Welty, L. J.

  National Heart, Lung, and Blood Institute

  12/6/21 → 11/30/26

  Project: Research project

  • Pregnancy Outcome 100%
  • Cardiovascular Diseases 59%
  • Pregnancy 34%
  • National Heart, Lung, and Blood Institute (U.S.) 12%
  • Placentation 11%

• Prot#EX9536-4665: Effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Subjects with Obesity-Related Heart Failure with Preserved Ejection Fraction

  Patel, R. B.

  Novo Nordisk Inc.

  12/2/21 → 12/2/24

  Project: Research project

• Prot#AG10-304: An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)

  Shah, S. J.

  Pharmaceutical Research Associates, Inc., Eidos Therapeutics, Inc.

  12/1/21 → 12/1/24

  Project: Research project